Friday, 22 Jun 2018

You are here

Cancer Risk Raised in Psoriatic Arthritis

Patients with psoriatic arthritis (PsA) were at increased risks for malignancy, and possibly more so if they were treated with conventional disease-modifying antirheumatic drugs (DMARDs), a meta-analysis found.

In nine cohort studies that included more than 43,000 PsA patients, the pooled relative risk for overall malignancy was 1.29 (95% CI 1.04-1.60) compared with the general population, according to Yunyun Fei, MD, and colleagues from Peking Union Medical College in Beijing.

And for patients who were using conventional DMARDs, the pooled relative risk was 1.75 (95% CI 1.40-2.18), the researchers reported in Seminars in Arthritis & Rheumatism.

Clinical efficacy has been clearly demonstrated for various DMARDs and biologics, but it's not yet clear if there are long-term risks for rare adverse events such as cancer with these treatments. Some studies have found increased risks of malignancies such as breast cancer, while other reports found no increases among patients with PsA.

Because of the underlying immune system abnormalities and immunosuppressive effects of medications used for PsA, the researchers sought to analyze the available data to provide an up-to-date estimate of cancer risks. The team therefore undertook a systematic literature review and meta-analysis of studies published through March 2018 that included at least 20 patients, had sufficient duration of follow-up, and provided adequate detail on treatment regimens.

Unlike for patients treated with conventional DMARDs, no risks were seen for overall malignancy among those receiving biologic therapies, with a pooled relative risk of 0.957 (95% CI 0.80-1.14).

The meta-analysis also identified an elevated risk for nonmelanoma skin cancer, with a pooled relative risk of 2.46 (95% CI 1.84-3.28), but not for other specific cancers:

  • Urinary tract cancers, RR 1.07 (95% CI 0.90-1.27)
  • Digestive tract cancers, RR 0.82 (95% CI 0.62-1.09)
  • Lymphoid/hematopoietic and related malignancies, RR 1.17 (95% CI 0.93-1.46)
  • Breast cancer, RR 0.98 (95% CI 0.85-1.14)
  • Respiratory tract cancers, RR 1 (95% CI 0.73-1.36)

The authors noted that there was a high degree of heterogeneity among the studies (I2 =71.37%), but no publication bias was evident.

The observation in this meta-analysis that treatment with biologics was not associated with an increased risk of malignancy concurs with what was seen in the Safety Assessment of Biological Therapeutics study, which included almost 30,000 patients with rheumatoid arthritis, PsA, psoriasis, and inflammatory bowel disease treated with tumor necrosis factor (TNF) inhibitors. In that study, no significant increased risk was seen for any of the 10 most common cancers among anti-TNF-treated patients compared with patients treated with other therapies.

As to why conventional DMARD treatment might be associated with increased risk, the authors of the meta-analysis pointed to anti-metabolite properties and decreased anti-cancer surveillance by the immune system with drugs such as methotrexate as possibly playing a role. However, the team noted that studies considering this concern had small numbers of patients and lacked adequate controls, "leaving it open to interpretation whether cancer risk is associated with the therapeutic agent or with the disease itself. No clear conclusion can be drawn regarding whether conventional DMARD use may increase cancer risk."

With regard to the risk of nonmelanoma skin cancer, the authors noted that risks with immunosuppressive medications have been demonstrated in the transplant literature, and a large North American registry of patients with PsA found an incidence rate of 0.21 per 100 patient-years for nonmelanoma skin cancer. "It seems that more attention should be paid to monitoring nonmelanoma skin cancer during PsA treatment," Fei and colleagues cautioned.

However, they also pointed out that none of the studies included in their meta-analysis reported on the use of high-dose psoralen and ultraviolet A radiation treatments for psoriasis, which could influence skin cancer risks.

"Large-scale longitudinal studies will be essential for drawing firm conclusions regarding PsA-associated risk for malignancy, including the effects of treatment and the identification of disease- and person-specific risk factors."

A limitation of the study, the researchers said, was the inadequate detail in some studies about specific cancer diagnoses.

The study was funded by the National Natural Science Foundation of China and the Chinese Academy of Medical Sciences Initiative for Innovative Medicine.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cosentyx Gets Radiographic Protection Indication for Psoriatic Arthritis

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).

Increased Risk of Infection in Psoriasis and Psoriatic Arthritis

As we gather more knowledge about psoriatic arthritis ( PsA) and psoriasis (PSO) over time, and achieve better outcomes with new therapies, more questions arise about quality of life, survival  and comorbidities in PsA and PSO. Similarly to RA, we learned about increased risk of CVD and malignancy. With more data compiled in cohorts it is possible now to ask the same questions as we asked in RA.

Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA

Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides. A single center cross -sectional observational study was designed to conduct deeper analysis of Cardiovascular Risk Factors (CVRF) in patients with PsA, PSO without arthritis and SpA without PSO (THU 0297).

MRI Imaging for Sacroiliitis Requires Bone Marrow Edema for Reliability

de Winter and colleagues from the Netherlands have reported on magnetic resonance imaging of the sacroiliac joints of healthy subjects, patients with axial spondyloarthritis, runners and those with chronic back pain, and found a high incidence of sacroiliitis in many, but that deep bone marrow edema was most specific for those with axial SpA.

Trends in Psoriatic Arthritis Treatment 2004-2015

Lee and colleagues from Brigham and Women's Hospital have analyzed the last decade of disease‐modifying antirheumatic drugs (DMARDs) use in patients with psoriatic arthritis (PsA) and found nearly 40% were treated with a bDMARD, along with a decreasing trend in complete DMARD discontinuations.